2019-002615-25: A clinical trial to be conducted in many hospitals and in different countrieswith the medicinal substance Regadenoson to be used in a type of heart scan called ‘radionuclide myocardial perfusion imaging’ to see the blood flow in the heart muscle in patients aged between 1 month - 18 years. |
|
|
| Not yet recruiting | 1/2 | 54 | Europe | Regadenoson, [-], Solution for injection, Rapiscan | GE Healthcare Ltd., GE HEALTHCARE, GE Healthcare Ltd. | Patients who need to undergo a clinically indicated pharmacologic stress perfusion CMR test and who are considered fit for a pharmacological stress perfusion CMR by the investigator. The pharmacologic stress perfusion CMR may be performed in patients for further evaluation of cardiovascular conditions or diseases, such as, but not limited to, Kawasaki disease, congenital heart diseases, congenital coronary abnormalities, and post-cardiac surgery / transplantation, etc., Rapiscan is used in a type of heart scan called myocardial perfusion imaging. It belongs to a group of medicines called coronary vasodilators. It makes heart arteries expand and heart rate increase., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
